A Randomized Study of Cervical Priming With Misoprostol Prior to Elective First Trimester Pregnancy Termination
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||A Randomized Study of Cervical Priming With Misoprostol Prior to Elective First Trimester Pregnancy Termination: Effects on Pain, Ease of Procedure and Complications|
- The first assessment will be a Visual Box Scale (VBS) for pain administered while the patient is undergoing the abortion procedure.
- After the procedure the physician will estimate the patient’s pain using a VBS. The physician will also estimate the ease of the procedure using a different VBS.
|Study Start Date:||May 2001|
|Estimated Study Completion Date:||May 2006|
Previous studies suggest that cervical priming with misoprostol may facilitate vacuum aspiration for first trimester termination by inducing cervical dilation. This medication is used routinely at some abortion clinics, not at all at others and is used sporadically at most Kaiser facilities. The present study is designed to investigate whether the use of misoprostol noticeably improves the clinical experience. We will determine whether use of misoprostol compared with placebo during first trimester abortion 1) positively impacts ratings of pain experienced by the patient, 2) positively impacts physicians’ ratings regarding difficulty of the procedure, and 3) reduces complications.
Misoprostol is effective for cervical priming prior to vacuum aspiration for first trimester pregnancy termination.2 Previous studies examined dose3,4, route of administration (oral5 or vaginal6,7) and time interval to allow maximum dilation while limiting side effects and bleeding prior to procedure.8,9,10 There is evidence supporting a specific dose, route and time interval.10 Previous studies also examined amount of bleeding, length of procedure, force used to dilate the cervix, and cervical dilation in mm.10 However, it is unknown whether these statistically significant changes translate into clinically relevant changes. For example, Ngai et al.10 report that the blood loss is significantly decreased. However, the mean blood loss differed at most by 68 ml. It is widely accepted that during surgical procedures a difference of 68 ml of blood will not change the patient’s hematocrit or postoperative clinical course. In the same study preoperative baseline cervical dilation was only 1.7 mm different, also found to be statistically significant but there is no evidence that this difference changes the clinical experience for either the physician or the patient. All previous studies reviewed were also performed with the patient under general anesthesia so the patient’s perception of pain was not examined. Because the majority of first trimester terminations in the U.S. are done with the patient awake, it is important to consider pain.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00310921
|United States, California|
|Kaiser Permanente, Department of OB/GYN|
|San Francisco, California, United States, 94115|
|Principal Investigator:||Seth Feigenbaum, M.D.||Kaiser Permanente Medical Group, Inc.|